Bone News and Research

RSS

Gene therapy shows positive effects in rat models of PAH: Researchers

Gene therapy has been shown to have positive effects in rat models of pulmonary arterial hypertension, according to researchers at the University of Adelaide in Australia.

20 May 2010

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.

20 May 2010

Riga to host 3rd Baltic Congress of Osteoporosis

Riga, Latvia will be the venue for the 3rd Baltic Congress of Osteoporosis which will take place on September 3-4, 2010. The congress, to be held in English, is jointly organized by the Latvian Osteoporosis and Bone Metabolism Diseases Association, Lithuanian Osteoporosis Foundation, Lithuanian Association of Metabolic Bone Diseases and the Estonian Osteoporosis Society.

19 May 2010

Natural molecule in body counters progression of osteoarthritis: Scientists

An international team of scientists from The Scripps Research Institute in California and the National Research Institute for Child Health and Development in Japan has discovered that a natural molecule in the body counters the progression of osteoarthritis. The findings could one day lead to new therapies for some common diseases of aging.

19 May 2010

Tel Aviv University researcher develops tool to measure tissue damage in bed-ridden, paralyzed patients

There's currently no reliable tool to help prosthetic developers fit artificial limbs without ensuing discomfort or pain, or tell medical personnel when bed-ridden patients need to be moved to avoid bedsores and other problems.

19 May 2010

Two common operations for SUI help women achieve similar levels of dryness: Study

Two common operations for stress urinary incontinence help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine to coincide with a presentation at the annual meeting of the American College of Obstetrics and Gynecology. Results will appear in the June 3 print edition.

19 May 2010

Researchers discover biological pathway signature of ccRCC

By examining expression of every human gene in clear cell renal cell carcinoma compared to normal kidney cells, researchers at Mayo Clinic's campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat kidney cancer.

19 May 2010

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Human stem cells administered intravenously can restore alveolar epithelial tissue to a normal function in a novel ex vivo perfused human lung after E. coli endotoxin-induced acute lung injury, according to research from the University of California San Francisco.

18 May 2010

New book offers practical knowledge on celiac disease, gluten-related disorders

A new book from the American Gastroenterological Association offers broad and practical knowledge on celiac disease and gluten-related disorders, empowering those who are undiagnosed and those living with the disease to achieve the best possible health and well-being.

18 May 2010

Researchers treat undiagnosed FIM with experimental stem cell transplant

Researchers at the Queensland Institute of Medical Research and the Royal Brisbane Women's Hospital have identified a previously undiagnosed condition and successfully treated it by performing an experimental stem cell transplant.

18 May 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

Australian doctors identify new disease and devise its cure

A team of Australian doctors have identified a new disease and its cure. In their report published in the journal Clinical Infectious Diseases the doctors from The Queensland Institute of Medical Research (QIMR) report a case of a young NSW woman ill for almost a decade with repeated hospitalizations. She is now said to be suffering from a diseases that disabled the signaling processes of her immune system. The diseases is not named yet. Dr Maher Gandhi, head of QIMR's Immunohemotology Laboratory believes there are more cases of this disease. He said this Monday, “I haven't got a name for it other than T-cell signaling defect of which I assume there are quite a few different types… There are no recorded cases of this in the literature. Katie is unique ... I think we're at the tip of the iceberg here.”

17 May 2010

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Hawthorn Pharmaceuticals, Inc. today announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility.

17 May 2010

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy (DCM). Treatment was performed by interventional cardiologist Timothy D. Henry, M.D., FACC, at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis, MN.

17 May 2010

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies, Inc. today announced its financial results for the first quarter 2010.

17 May 2010

Athersys presents data supporting MultiStem programs

Athersys, Inc. today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity.

15 May 2010

Winners of 2010 IADR/GSK Innovation in Oral Care Awards announced

The International Association for Dental Research and GlaxoSmithKline Consumer Healthcare today announced the 2010 winners of the annual IADR/GSK Innovation in Oral Care Awards. The three prestigious awards recognize research in innovative oral care technologies that may maintain and improve oral health and the quality of life.

15 May 2010

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Amgen Inc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa® (zoledronic acid).

15 May 2010

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

SANUWAVE Health, Inc.,, an emerging medical technology company focused on regenerative medicine, today reported financial results for the three months ended March 31, 2010 and provided a business update.

14 May 2010

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

Interleukin Genetics, Inc. announced today financial and operational results for the first quarter ended March 31, 2010.

14 May 2010

Bone News and Research

Gene therapy shows positive effects in rat models of PAH: Researchers

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

Riga to host 3rd Baltic Congress of Osteoporosis

Natural molecule in body counters progression of osteoarthritis: Scientists

Tel Aviv University researcher develops tool to measure tissue damage in bed-ridden, paralyzed patients

Two common operations for SUI help women achieve similar levels of dryness: Study

Researchers discover biological pathway signature of ccRCC

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

New book offers practical knowledge on celiac disease, gluten-related disorders

Researchers treat undiagnosed FIM with experimental stem cell transplant

152 research and training grants awarded to researchers at 93 institutions nationwide

Australian doctors identify new disease and devise its cure

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Emisphere Technologies first-quarter net loss increases to $18.5 million

Athersys presents data supporting MultiStem programs

Winners of 2010 IADR/GSK Innovation in Oral Care Awards announced

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News